KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non Operating Income: 2009-2011

Historic Other Non Operating Income for Rigel Pharmaceuticals (RIGL) over the last 1 years, with Mar 2011 value amounting to $15.1 million.

  • Rigel Pharmaceuticals' Other Non Operating Income fell 13.31% to $15.1 million in Q1 2011 from the same period last year, while for Mar 2011 it was $219.4 million, marking a year-over-year decrease of 1.94%. This contributed to the annual value of $2.4 million for FY2010, which is 98.32% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Other Non Operating Income stood at $15.1 million for Q1 2011, which was down 91.91% from $186.7 million recorded in Q4 2010.
  • In the past 5 years, Rigel Pharmaceuticals' Other Non Operating Income ranged from a high of $186.7 million in Q4 2010 and a low of $167,535 during Q3 2010.
  • For the 3-year period, Rigel Pharmaceuticals' Other Non Operating Income averaged around $65.1 million, with its median value being $23.9 million (2009).
  • Data for Rigel Pharmaceuticals' Other Non Operating Income shows a peak YoY increase of 32.65% (in 2010) and a maximum YoY decrease of 42.46% (in 2010) over the last 5 years.
  • Rigel Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $140.7 million in 2009, then spiked by 32.65% to $186.7 million in 2010, then declined by 13.31% to $15.1 million in 2011.
  • Its last three reported values are $15.1 million in Q1 2011, $186.7 million for Q4 2010, and $167,535 during Q3 2010.